HIPERFERRITINEMIA IN MYELODISPLASTIC SYNDROME (MSD) PATIENTS.CORELATION WITH EVOLUTION AND SURVIVAL
(Abstract release date: 05/19/16)
EHA Library. Ionita H. 06/09/16; 134827; PB1927
Prof. Hortensia Ionita
Contributions
Contributions
Abstract
Abstract: PB1927
Type: Publication Only
Background
Most myelodysplastic (MDS) patients have anemia and many of them require red blood cells (RBC) transfusions leading to iron overload. Hematological improvement during iron chelation therapy was first pointed out more than twenty years ago. This phenomenon seems to be more frequent after introduction of Deferasirox. The most simple test assessing iron overload is serum ferritin concentration .
Aims
Assessment of hyperferritinemia incidence in MDS patients at the moment of MDS diagnosis, and correlation between ferritin level and evolution an survival in patients diagnosed with MDS.
Methods
The retrospective data collection from a single center experience (Department of Hematology County Hospital, Timisoara, Romania) between January 2005 and December 2014 included 121 patients (73men and 48 women) with MDS. All the patients had complete blood count and serum ferritin level, and complete follow-up data.
Results
Ferritin level above1000 ng/mL was found in 45 patients (31%) (Group 1) and ferritin level ≤1000ng/mL in 76 patients (69%) (Group 2). Most patients with significant hiperferritinemia,were RBC transfusion dependent (78% of patients). Among patients with ferritin level ≤1000 ng/mL, 48% were RBC transfusion dependent. Serum hemoglobin concentration was lower in Group 1 patients in comparison with Group 2 patients (6.2 g/dL vs 9,3 g/dL, p< 0,001). The most frequent MDS subtype in Group 1, were patients with refractory anemia (RA) (32%), compared with patients with ferritin ≤1000 ng/mL - 15% (p<0,04). According to IPSS score, there were no differences between studied groups. Median follow up was 15 months. There was an improved overall survival (OS) in RBC transfusion independent patients compared to RBC transfusion dependent patients, but mean OS was not significantly statistically different in studied groups. No correlation was found between ferritin level and time to acute myeloid leukemia (AML) transformation.
Conclusion
Hiperferritinemia>1000 ng/mL does not influence survival and time to AML transformation in MDS patients. The most frequent MDS subtype in patients with ferritin level>1000 ng/mL was MDS RA. Among patients with ferritin level >1000 ng/mL 76% were RBC dependent.
Session topic: E-poster
Type: Publication Only
Background
Most myelodysplastic (MDS) patients have anemia and many of them require red blood cells (RBC) transfusions leading to iron overload. Hematological improvement during iron chelation therapy was first pointed out more than twenty years ago. This phenomenon seems to be more frequent after introduction of Deferasirox. The most simple test assessing iron overload is serum ferritin concentration .
Aims
Assessment of hyperferritinemia incidence in MDS patients at the moment of MDS diagnosis, and correlation between ferritin level and evolution an survival in patients diagnosed with MDS.
Methods
The retrospective data collection from a single center experience (Department of Hematology County Hospital, Timisoara, Romania) between January 2005 and December 2014 included 121 patients (73men and 48 women) with MDS. All the patients had complete blood count and serum ferritin level, and complete follow-up data.
Results
Ferritin level above1000 ng/mL was found in 45 patients (31%) (Group 1) and ferritin level ≤1000ng/mL in 76 patients (69%) (Group 2). Most patients with significant hiperferritinemia,were RBC transfusion dependent (78% of patients). Among patients with ferritin level ≤1000 ng/mL, 48% were RBC transfusion dependent. Serum hemoglobin concentration was lower in Group 1 patients in comparison with Group 2 patients (6.2 g/dL vs 9,3 g/dL, p< 0,001). The most frequent MDS subtype in Group 1, were patients with refractory anemia (RA) (32%), compared with patients with ferritin ≤1000 ng/mL - 15% (p<0,04). According to IPSS score, there were no differences between studied groups. Median follow up was 15 months. There was an improved overall survival (OS) in RBC transfusion independent patients compared to RBC transfusion dependent patients, but mean OS was not significantly statistically different in studied groups. No correlation was found between ferritin level and time to acute myeloid leukemia (AML) transformation.
Conclusion
Hiperferritinemia>1000 ng/mL does not influence survival and time to AML transformation in MDS patients. The most frequent MDS subtype in patients with ferritin level>1000 ng/mL was MDS RA. Among patients with ferritin level >1000 ng/mL 76% were RBC dependent.
Session topic: E-poster
Abstract: PB1927
Type: Publication Only
Background
Most myelodysplastic (MDS) patients have anemia and many of them require red blood cells (RBC) transfusions leading to iron overload. Hematological improvement during iron chelation therapy was first pointed out more than twenty years ago. This phenomenon seems to be more frequent after introduction of Deferasirox. The most simple test assessing iron overload is serum ferritin concentration .
Aims
Assessment of hyperferritinemia incidence in MDS patients at the moment of MDS diagnosis, and correlation between ferritin level and evolution an survival in patients diagnosed with MDS.
Methods
The retrospective data collection from a single center experience (Department of Hematology County Hospital, Timisoara, Romania) between January 2005 and December 2014 included 121 patients (73men and 48 women) with MDS. All the patients had complete blood count and serum ferritin level, and complete follow-up data.
Results
Ferritin level above1000 ng/mL was found in 45 patients (31%) (Group 1) and ferritin level ≤1000ng/mL in 76 patients (69%) (Group 2). Most patients with significant hiperferritinemia,were RBC transfusion dependent (78% of patients). Among patients with ferritin level ≤1000 ng/mL, 48% were RBC transfusion dependent. Serum hemoglobin concentration was lower in Group 1 patients in comparison with Group 2 patients (6.2 g/dL vs 9,3 g/dL, p< 0,001). The most frequent MDS subtype in Group 1, were patients with refractory anemia (RA) (32%), compared with patients with ferritin ≤1000 ng/mL - 15% (p<0,04). According to IPSS score, there were no differences between studied groups. Median follow up was 15 months. There was an improved overall survival (OS) in RBC transfusion independent patients compared to RBC transfusion dependent patients, but mean OS was not significantly statistically different in studied groups. No correlation was found between ferritin level and time to acute myeloid leukemia (AML) transformation.
Conclusion
Hiperferritinemia>1000 ng/mL does not influence survival and time to AML transformation in MDS patients. The most frequent MDS subtype in patients with ferritin level>1000 ng/mL was MDS RA. Among patients with ferritin level >1000 ng/mL 76% were RBC dependent.
Session topic: E-poster
Type: Publication Only
Background
Most myelodysplastic (MDS) patients have anemia and many of them require red blood cells (RBC) transfusions leading to iron overload. Hematological improvement during iron chelation therapy was first pointed out more than twenty years ago. This phenomenon seems to be more frequent after introduction of Deferasirox. The most simple test assessing iron overload is serum ferritin concentration .
Aims
Assessment of hyperferritinemia incidence in MDS patients at the moment of MDS diagnosis, and correlation between ferritin level and evolution an survival in patients diagnosed with MDS.
Methods
The retrospective data collection from a single center experience (Department of Hematology County Hospital, Timisoara, Romania) between January 2005 and December 2014 included 121 patients (73men and 48 women) with MDS. All the patients had complete blood count and serum ferritin level, and complete follow-up data.
Results
Ferritin level above1000 ng/mL was found in 45 patients (31%) (Group 1) and ferritin level ≤1000ng/mL in 76 patients (69%) (Group 2). Most patients with significant hiperferritinemia,were RBC transfusion dependent (78% of patients). Among patients with ferritin level ≤1000 ng/mL, 48% were RBC transfusion dependent. Serum hemoglobin concentration was lower in Group 1 patients in comparison with Group 2 patients (6.2 g/dL vs 9,3 g/dL, p< 0,001). The most frequent MDS subtype in Group 1, were patients with refractory anemia (RA) (32%), compared with patients with ferritin ≤1000 ng/mL - 15% (p<0,04). According to IPSS score, there were no differences between studied groups. Median follow up was 15 months. There was an improved overall survival (OS) in RBC transfusion independent patients compared to RBC transfusion dependent patients, but mean OS was not significantly statistically different in studied groups. No correlation was found between ferritin level and time to acute myeloid leukemia (AML) transformation.
Conclusion
Hiperferritinemia>1000 ng/mL does not influence survival and time to AML transformation in MDS patients. The most frequent MDS subtype in patients with ferritin level>1000 ng/mL was MDS RA. Among patients with ferritin level >1000 ng/mL 76% were RBC dependent.
Session topic: E-poster
{{ help_message }}
{{filter}}